1003298-73-4

Basic information

• Product Name: 4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96%
• Synonyms: 4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96%;2,6-Difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile
• CAS NO: 1003298-73-4
• Molecular Formula: C₁₃H₁₄BF₂NO₂
• Molecular Weight: 265.0635664
• Mol File: 1003298-73-4.mol

Chemical Properties

• Boiling Point: 342.2±42.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.18±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96%(1003298-73-4)
• EPA Substance Registry System: 4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96%(1003298-73-4)

Safety Data

• Hazardous Substances Data: 1003298-73-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96% is used as a reagent in organic synthesis for its ability to participate in a variety of chemical reactions, including cross-coupling and Suzuki-Miyaura reactions, due to its boronic acid functionality.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96% is used as a building block for the development of new pharmaceuticals, leveraging its unique structure to create novel compounds with potential therapeutic applications.
Used in Chemical Research:
4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96% is also utilized in academic and industrial research settings as a tool to explore new reaction pathways and mechanisms, taking advantage of its high purity and reactivity.
Used in the Production of Advanced Materials:
4-Cyano-3,5-difluorobenzeneboronic acid pinacol ester, 96% is employed in the synthesis of advanced materials, such as conductive polymers and specialty coatings, where its fluorinated and cyano-substituted aromatic structure imparts desirable properties to the final product.

Upstream product

• 123843-67-4 4-bromo-2,6-difluorobenzonitrile 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 861710-03-4 3,5-difluoro-4-cyanophenylboronic acid 

Relevant articles and documents

C1-, C2-, and C3-Modified Carbazole Derivatives as Promising Host Materials for Phosphorescent Organic Light-Emitting Diodes

Herein we unveiled the synthetic approach to C1-, C2-, and C3-modified carbazoles for the first time and designed high-triplet-energy bipolar host materials for green phosphorescent organic light-emitting devices. The compounds revealed excellent performa

Two-channel emission controlled by a conjugation valve for the color switching of thermally activated delayed fluorescence emission

The development of two-channel emission featuring deep-blue thermally activated delayed fluorescent (TADF) emitters is highly challenging due to their unavoidably extended conjugated structures. Herein, we propose a simple and effective strategy involving engineering of the interconnection position and formation of a "conjugation valve" to control their emission colors, including enabling emission of deep-blue light with an uncompromised external quantum efficiency (EQE). Two novel TADF emitters, namely 2,3′,4,5′-tetra(9H-carbazol-9-yl)-[1,1′-biphenyl]-3,4′-dicarbonitrile (34CzBN) and 3,3′,5,5′-tetra(9H-carbazol-9-yl)-[1,1′-biphenyl]-4,4′-dicarbonitrile (44CzBN), were developed to produce a two-channel-emission path by directly connecting two identical TADF units in two different ways to produce different degrees of conjugation. The non-conjugative mode of connection in 34CzBN resulted in severe steric hindrance at the central core, which interrupted the extensive conjugation and resulted in significant blue-shifts of the absorption and emission compared to those of its isomer 44CzBN. The two-channel-emission process provided a four-times higher EQE than the single-channel-emission process. The 34CzBN-based TADF device demonstrated deep-blue emission with color coordinates of (0.14, 0.14) due to a closed conjugation channel, and displayed an EQE of 15.2%. In contrast, the 44CzBN device showed green emission with color coordinates of (0.20, 0.44), due to the open conjugation channel, and an EQE of 13.8%. Additionally, the emission peak in the spectrum of the 34CzBN-based device became narrow (full width at half-maximum of ～63 nm) due to restricted molecular motion resulting from the interlocked carbazole donor at the central core.

COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES

The present disclosure relates to compounds capable of emitting delayed fluorescence, and uses of the compounds in organic light-emitting diodes.

ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES

The invention relates to an organic molecule for the use in optoelectronic devices. According to the invention, the organic compound has - a first chemical moiety with a structure of formula (I) and - three second chemical moieties, each independently fro

BENZIIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS SODIUM CHANNEL MODULATORS

The invention relates to benzimidazole and imidazopyridine derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new Nav1.8 modulators of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7. X and Y are as defined in the description. Nav1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS

The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, where R1-R3 and Y are defined in the description, and its use in the treatment of disorders in which pi3 kinase is imp